Physician profile
Marc Mayer
NPI 1720083132
$7,277.98
in general payments reported to CMS, 2019-2025
44 companies · $1,482 in 2025
The $1,482 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,504 · 2020: $811 · 2021: $154 · 2022: $948 · 2023: $1,122 · 2024: $1,257 · 2025: $1,482.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,861.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,860.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $730.83 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Pfizer INC. | $690.82 | 2019-2025 | |
| Novo Nordisk INC | $587.58 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $557.13 | 2023-2025 | |
| Exact Sciences Corporation | $554.51 | 2023-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $518.48 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Glaxosmithkline, LLC. | $474.71 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Amgen INC. | $304.98 | 2019-2025 | Repatha, Otezla, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $287.45 | 2019-2023 | Trulance, Xifaxan |
| Merck Sharp & Dohme LLC | $284.84 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Abbott Laboratories | $271.23 | 2022-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $254.39 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $240.27 | 2019-2025 | Jardiance, Spiriva Respimat |
| Janssen Pharmaceuticals, INC | $150.18 | 2019-2025 | Spravato |
| Sanofi Pasteur INC. | $144.03 | 2019-2020 |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $134.88 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $130.11 | 2022-2025 | |
| Dexcom, INC. | $125.26 | 2022-2025 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $102.35 | 2025 | Korlym |
| Amarin Pharma, INC. | $79.76 | 2019-2020 | |
| Heartflow, INC. | $76.61 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $72.74 | 2025 | Camzyos, Eliquis |
| Mannkind Corporation | $51.83 | 2019 | |
| Vertos Medical, INC. | $39.40 | 2019 | |
| Azurity Pharmaceuticals, INC. | $35.41 | 2024 | Edarbyclor |
| Edwards Lifesciences Corporation | $32.78 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Echosens North America, INC. | $30.78 | 2024 | Fibroscan |
| Takeda Pharmaceuticals U.S.A., INC. | $29.66 | 2019-2023 | Entyvio |
| Genentech USA, INC. | $29.05 | 2019-2020 | |
| Cvrx, INC. | $26.79 | 2024 | Barostim Neo System |
| Kowa Pharmaceuticals America, INC. | $24.65 | 2020 | |
| Optos, INC. | $20.14 | 2020 | |
| Baxter Healthcare | $18.84 | 2025 | Hillrom - Cardiac Ambulatory Monitor |
| Paratek Pharmaceuticals, INC. | $18.72 | 2025 | Nuzyra |
| Astellas Pharma US INC | $18.10 | 2024 | Veozah |
| Boston Scientific Corporation | $17.94 | 2025 | Lithovue |
| Phathom Pharmaceuticals, INC. | $15.02 | 2025 | Voquezna |
| Phadia US INC. | $14.69 | 2023 | Immunocap |
| Kiniksa Pharmaceuticals, Ltd. | $14.64 | 2022 | |
| Modernatx, INC. | $13.85 | 2025 | Mresvia |
| Kiniksa Pharmaceuticals International, Plc | $13.57 | 2024 | Arcalyst |
| Otsuka America Pharmaceutical, INC. | $13.27 | 2024 | Jynarque |
| Aytu Biopharma, INC. | $13.06 | 2019 | |
| Seqirus USA INC | $12.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Mayer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.